Purpose This study aims to (1) summarise and critically evaluate the effects of neuromuscular electrical stimulation (NMES) on indices of health and quality of life (QoL) in adult cancer survivors, (2) assess the safety of NMES as a rehabilitation method in this population, and (3) identify commonly used NMES treatment parameters and describe treatment progression. Methods A systematic search of four electronic databases targeted studies evaluating the effects of NMES on physical function, aerobic fitness, muscle strength, body composition, and health-related quality of life (HR-QoL) in adult cancer survivors, published through March 2018. Two reviewers independently reviewed and appraised the risk of bias of each study. Results Nine studies were included. Meta-analyses found that the overall pooled effect favoured NMES for improving muscle strength, but the standardised mean difference was not significant (0.36; 95% CI − 0.25, 0.96). Further meta-analyses indicated that NMES significantly improved HR-QoL (0.36; 95% CI 0.10, 0.62), with notable gains identified under the subcategories QoL Function (0.87; 95% CI 0.32, 1.42). Current NMES prescription is not standardised and NMES is prescribed to target secondary complications of treatment. Risk of bias was high for most studies. Conclusions NMES use in adult cancer survivors is an emerging field and current literature is limited by studies of poor quality and a lack of adequately powered RCTs. Existing evidence suggests that NMES is safe and may be more effective than usual care for improving HR-QoL. Prescription and progression should be tailored for the individual based on functional deficits. Although cancer treatments (e.g. chemotherapy and hormone therapy) can be efficacious, they can lead to long-term side effects such as fatigue, muscle loss, and reductions in functional capacity [5] . Exercise which targets both the neuromuscular and cardiovascular systems is currently recommended to help offset some of the complications of treatment with guidelines recommending 150 mins of moderate or 75 mins of vigorous aerobic exercise coupled with two to three resistance training (RT) sessions per week regardless of disease progression [6] .
Annual cancer diagnosis rates (> 14 million per year) are set to increase by 50% before 2030 [1] . However, mortality from cancer is decreasing. Five-year survival rates in the USA for all cancer combined have improved by almost 20%, from 49% in the 1970s to~70% in 2016 [2] . Similar trends have been reported in Europe with mortality rates in men and women falling by 8 and 3%, respectively, since 2011 [3] . These favourable trends are linked to improved screening and more effective antineoplastic treatments [4] .
Although cancer treatments (e.g. chemotherapy and hormone therapy) can be efficacious, they can lead to long-term side effects such as fatigue, muscle loss, and reductions in functional capacity [5] . Exercise which targets both the neuromuscular and cardiovascular systems is currently recommended to help offset some of the complications of treatment with guidelines recommending 150 mins of moderate or 75 mins of vigorous aerobic exercise coupled with two to three resistance training (RT) sessions per week regardless of disease progression [6] .
Nevertheless, exercise is not always possible due to treatment complications or contraindications to aerobic exercise and RT. Reports suggest that only~35% of cancer survivors achieve current recommendations [7, 8] with breathlessness, fatigue, weakness, and poor balance cited as common issues affecting basic exercise participation such as walking [9] . Thus, pragmatic alternatives to traditional exercise methods are required.
Neuromuscular electrical stimulation (NMES) involves controlled muscular contractions generated by electrical impulses delivered through surface electrodes, usually placed on major muscle groups such as the quadriceps and hamstrings [10] . The evoked contractions have proven efficacy in improving muscle strength and cardiorespiratory fitness across a variety of populations [11] [12] [13] [14] [15] [16] [17] [18] . Thus, physiciansupervised NMES exercise to enhance the neuromuscular and cardiovascular systems has applicability within the cancer population to prevent the complications associated with treatment and improve health-related quality of life (HR-QoL). However, NMES uptake clinically is low [19] and currently no published, high-level evidence supports its application in cancer survivorship.
Therefore, the objectives of this review are to evaluate published research investigating the use of NMES exercise in adult cancer survivors, synthesise the evidence evaluating its application in improving physical function and HR-QoL, and assess the safety of NMES exercise in cancer populations and determine if specific prescription and progression patterns could be identified with NMES application in cancer survivorship.
Methods
A systematic search and review of the literature was conducted using the PRISMA guidelines [20] . The following databases were searched up to March 2018: PubMed , EMBASE (1947 EMBASE ( -2018 , CINAHL (1982 CINAHL ( -2018 , and The Cochrane Library .
Eligibility criteria
Selection criteria for inclusion in this review comprised of the following: (1) article or abstract of original research, (2) population of adult cancer survivors, (3) interventions detailing NMES, and (4) measurement of outcomes pre-NMES and post-NMES to evaluate treatment effectiveness. No limitations were placed by study methodology to allow for a more comprehensive overview of this nascent area.
Exclusion criteria included studies involving transcutaneous electrical stimulation (TENS) for cancer pain or spinal cord stimulation.
Search
A search strategy (Appendix 1), guided by an institutional liaison Librarian, was based on the PICO method. The population was adult cancer survivors, the intervention was NMES, the comparator was no intervention or standard care and outcomes were physical function, aerobic fitness (cardiovascular capacity (VO 2max ) or VO 2peak or submaximal exercise capacity), muscle strength, body composition, and HR-QoL. Figure 1 details the study selection process. Identified studies were screened by title by one reviewer (DO'C). Remaining studies were independently screened by abstract by two reviewers (DO'C., OL). Identified full text manuscripts were again independently reviewed by two reviewers (DO'C., OL). Reasons for exclusion were recorded.
Study selection

Data collection process
Two reviewers (DO'C and OL) extracted data variables: type of study, study population (age, sex, disease type, and disease stage), intervention, outcome measures, and results (Table 1 ). In addition, NMES intervention prescription and progression data were extracted using frequency, intensity, type, and time (FITT) along with reported safety/adverse events ( Table 2) .
Quality assessment
Included studies were assessed independently by two reviewers (DO'C and OL) using the Effective Public Health Practice Project Quality Assessment Tool (EPHPP). In addition, the Cochrane Risk of Bias Tool was used for randomised controlled trials (RCTs). Disagreements were resolved by consensus.
Data synthesis
A narrative approach to analysis was first proposed, summarising all included studies by outcomes of interest. Secondary outcomes of NMES prescription and progression, and safety were also summarised narratively. Where two or more RCTs measured the same outcome, meta-analysis was proposed whereby differences between NMES-based interventions and comparator groups from pre-to post intervention would be calculated using Review Manager (v5.2) software. Continuous outcome measures would be expressed as the mean difference from pre-to post treatment in each group and variances derived from standard deviations. Where studies reported median and ranges, these would be converted to mean and standard deviation using a previously published method [30] . A fixed effects inverse-variance meta-analysis for mean differences with 95% confidence intervals (CI) between NMES-based interventions and control groups was proposed. A small number of studies were anticipated in this area, making it difficult to estimate the between studies variance with any precision. Where treatment outcomes were measured using different outcome measures, a standardised mean difference was calculated and where measured at more than one time point, the last measurement was used in the metaanalysis conducted. Sub-analysis for distinct follow-up periods would be conducted, where data permit. Figure 1 presents the flowchart of the study selection process. A total of 896 studies were identified from the databases. Eight full text articles and one abstract were included for final analysis: four RCTs [21, 25, 26, 28] , one case control study [24] , three interventional cohort studies [23, 27, 29] , and one case report [22] . Authors were contacted for further information for four additional studies identified [31] [32] [33] [34] . Following three contact attempts with the corresponding authors, studies were excluded where no response was received.
Results
Study selection
Risk of bias within studies
The overall risk of bias was deemed high in three RCTs [21, 25, 26] , with one study marked as unclear [28] . When all studies were evaluated using the EPHPP tool, two of the nine studies received a strong global rating for quality [21, 23] , five a moderate quality rating [22, 25, 26, 28, 29] , and one was rated as weak [24] . With limited data available to the reviewers, the abstract included in the review [27] was also rated as weak.
Participant demographics
A total of 229 adult cancer survivors from the 9 studies were included in this review. Of these, 111 were men (48.5%) and 
Cancer types
The types of cancer were breast cancer [21] , non-small cell lung cancer (NSCLC) [25, 26] , metastatic lung cancer [22] , cerebral glioma [27] , nasopharyngeal carcinoma [24] , low rectal cancer [23] , and foregut cancers including liver, pancreas, and stomach [28] . One study comprised a heterogeneous group including lung (n = 5), gastrointestinal (n = 1), breast (n = 1), ovarian (n = 1), endometrial (n = 1), and haematological cancers (n = 1) [29] .
Intervention
Location Three interventions were home based [25, 26, 29] . Other locations included hospital outpatient departments [21] [22] [23] [24] , and in-patient hospital rehabilitation units [27, 28] . Five studies used an experimental control group. Two studies reported using a 'no NMES' treatment control group [25, 26] and two reported usual care controls [21, 24] . One study reported the contralateral limb as the control [28] . Three studies reported no control group [23, 27, 29] .
Evidence supporting NMES application in Cancer survivorship
Meta-analyses
Sufficient data were extracted from RCTs to enable metaanalysis of two outcomes of interest, muscle strength as measured by fixed [25] and manual muscle test dynamometry [26] , and HR-QoL as measured by the EORTC QLQ C-30 [26] and the FACT-B+4 [21] . In each measure, the higher the score, the better the outcome.
Strength Data were pooled from two RCT studies with a total of 44 participants with lung cancer (Fig. 2) [25, 26] . Compared to usual care controls, the standardised mean effect of the NMES intervention on muscle strength was not statistically significant (SMD 0.36; 95% CI −0.25, 0.96; Z = 1.15; p = 0.25).
Health-related quality of life Data were pooled from two RCT studies with a total of 60 participants with breast cancer or lung cancer (Fig. 3) [21, 26] . Compared to usual care controls, meta-analysis demonstrates that the standardised mean effect of an NMES intervention for HR-QoL was significantly greater (SMD 0.36; 95% CI 0.10, 0.62; Z = 2.69; p = 0.007). When 
Narrative summary of individual studies
Effects of NMES on body function and structure
Submaximal exercise capacity
Exercise capacity was measured using the 6-min walk test (6MWT) in two studies [22, 29] and the endurance shuttle walk test (ESWT) [25] in another. Maddocks et al. [25] in a RCT involving NSCLC patients, recording 0 or 1 on the Eastern Cooperative Oncology Group performance status and at least 4 weeks post treatment, reported no significant difference between the NMES and 'no NMES' groups in the ESWT (− 20 vs − 158 m, p = 0.27). Windholz et al. [29] in their prospective pilot study reported no significant change in 6MWT performance after the intervention period from baseline (− 21.1 m, p = 0.7). Crevenna et al. [22] in a case study reported improvements of 44% in 6MWT performance (420 to 603 m).
Functional strength
One study analysed functional strength using the timed up and go test (TUG) [22] . One study used the timed, repeated sit to stand test (STS) [29] . Windholz et al. [29] reported no significant change in STS time from pre-to post-NMES intervention (− 1.2 s, p = 0.3). Crevenna et al. [22] in their case report reported a 20% reduction in TUG performance with this equating to a 1 s reduction in time taken to complete the test (pre-6 s vs post-5 s).
Body composition
Dual Energy X-ray absorptiometry (DXA) was used to assess thigh and whole body lean tissue mass in one study [26] . No significant difference between the NMES and control groups was noted in thigh lean mass (p = 0.44) or whole body lean mass (p = 0.31).
Biomarkers of muscle hypertrophy and atrophy
One study assessed biomarkers of muscle hypertrophy and muscle atrophy [28] . After 4 days of 30-min/day NMES application, no significant effect of NMES treatment on IGF-1Ea mRNA was noted in the treated limb in comparison to the contralateral control limb (p = 0.516). Of note, total RNA content was 26% greater in the NMES-treated leg than in the contralateral control limb (9.6 vs 7.6 μg/mg; p = 0.033). In addition, sarcoplasmic protein content increased by 20%, and this change was significant when compared to the control limb (p = 0.029). NMES treatment had no effect on myofibrillar proteins (p = 0.393). In the NMES limb, the expression of ubiquitin-conjugated proteins of sarcoplasmic fraction were significantly less (−23%) than that of the control limb (p = 0.0005). Proteasome activity was significantly reduced in the NMES limb also (−34%) in comparison to the control (p = 0.048).
Effects of NMES on HR-QoL
Six studies measured HR-QoL using diverse outcome measures, often reflecting the cancer type or aim of treatment. One study [26] [26] reported no significant changes following NMES in the EORTC QLQ-C30's 6 subscales (General Health score, Physical, Role, Emotional, Cognitive, Social) when compared to 'no NMES' controls. Belmonte et al. [21] reported significant within group pre-vs post HR-QoL mean change scores in the NMES group across FACT-B+4 summary scores: FACT-General (p = 0.006), FACT-Breast (p = 0.013), and FACT-Trial Outcome Index (TOI) (p = 0.015). However, when mean change scores were compared, no significant difference was reported across the three HRQoL summary-scales (FACT-General, p = 0.197; FACTBreast, p = 0.130; FACT-TOI, p = 0.074). Lin et al. [24] in their case control study reported that FES significantly improved swallowing HR-QoL from 45.1 to 53.1 (p = 0.003). Kuo et al. [23] in their interventional cohort study reported significant improvements in the Wexner's score post-NMES treatment (17.74 vs 12.93; p < 0.001). Rozumenko and Khoroshun [27] reported the proportion of patients with a KPS > 70 score before treatment and post rehabilitation as the outcome of interest, noting an increase from 43.7 to 83.5%, and no p value was reported. The case report by Crevenna et al. [22] showed improvements in all HR-QoL scales of the SF-36 with the exception of the social functioning subscale.
Safety of NMES
Three studies reported no adverse events [22, 25, 26] in lung cancer populations when NMES was applied to the lower limbs. One study employing NMES for lymphedema treatment following breast cancer reported dermatological adverse events [21] , including erysipelas on the upper limb (n = 1), skin irritation (n = 1), and erythema on the back of the hand (n = 1). Four studies did not report adverse events as an outcome [23, 24, 28, 29] . In one study, available in abstract form, NMES safety was indeterminate, despite attempts to contact the authors [27] .
Stimulation parameters Three studies employed a biphasic symmetrical current [22, 25, 26] . Kuo et al. [23] reported a square waveform. Rozumenko and Khoroshun [27] reported an asymmetrical waveform. Four studies did not report waveform [21, 24, 28, 29] . Pulse frequency was reported in all studies (range 0.31-63.3 Hz). Pulse duration was reported in eight studies (range 250-700 μs). Duty cycles varied from 2 to 12 s in the on phase and 4 to 30 s in the off phase. Three studies commented on the rationale for protocol selection [22, 25, 26] , justifying for pragmatic reasons, protocols previously used successfully in chronic obstructive pulmonary disease (COPD), and in heart failure patients.
Electrode placement Two studies reported stimulation of the anterior thigh over the quadriceps [25, 26, 28] . One study reported the motor point of the vastus medialis oblique distally, and over the midpoint of the quadriceps muscle belly more proximally [29] . Crevenna et al. [22] reported quadriceps and gluteal stimulation. Belmonte et al. [21] stimulated areas corresponding to lymphnodal stations. Kuo et al. [23] stimulated the anal canal and Lin et al. [24] placed electrodes between the hyoid bone and thyroid cartilage. One study reported that electrodes were placed in areas according to the clinical indications of motional defects, although no further information was provided by the authors upon request [27] .
Session duration NMES session duration varied from 5 min [27] to 60 min [24] .
Duration of treatment Four studies reported treatment durations as the number of sessions delivered (4 sessions: [28] ; 12 sessions: [23] ; 15 sessions: [24] ; 7-12 sessions: [27] . The duration of NMES treatment reported in remaining studies in weeks varied from 2 weeks [21] to 11 weeks [26] .
FITT prescription and progression patterns Only four studies reported progression patterns [25] [26] [27] 29] . One study reported progression from 30 to 60 min/day after week 1 [25] . One reported progression from 5 to 15 min [27] . Two studies reported a progression in the proportion of the treatment which was active stimulation. This progressed weekly from 2 s on: 10 s off (11%) to 5 s on, 25 s off (18%) to 10s on, 30s off (25%) and constant there after [25, 26] .
Discussion
The overall findings of this study suggest that NMES may be more effective than standard care for improving HRQoL (Fig. 2) . The current evidence does not support the use of NMES over and above usual care for improving submaximal exercise capacity, functional capacity, or body composition. Meta-analysis of strength drawn from a total of 44 participants (Fig. 3) showed the overall pooled effect favouring application of NMES for improving muscle strength but results were non-significant. No major adverse events following NMES application in cancer survivors were reported in the studies reviewed. This paper provides a comprehensive overview of the current evidence base in NMES research and oncology, not limited by year, language, or study type. However, high risk of bias noted in three of the four RCTs limits the current conclusions relating to higher level evidence that can be drawn. This is clearly an emerging field with a lack of large, adequately powered RCTs.
Cancer survivors experience poorer HR-QoL in response to disease/treatment [35] . Therefore, this review evaluated the efficacy of NMES for improving domains of HR-QoL. Overall meta-analysis demonstrated effectiveness of NMES over standard care for improving HRQoL, and in particular function QoL. Conflicting findings were reported in overall studies and mediating factors such as fatigue and exercise intensity must be considered in the interpretation of the findings. Maddocks et al. [26] reported no significant differences between NMES and 'no NMES' control across six HR-QoL subscales in patients receiving chemotherapy. However, ongoing treatments are linked to increased fatigue levels [36] . Moderate to vigorous intensity voluntary exercise delivered during active treatment has been shown to improve HR-QoL and function QoL [35] . Crevenna et al. [22] reported both improvement in aerobic exercise capacity and better HR-QoL following NMES in a case study, with the exception of the 'social functioning' subscale. Therefore, moderate to vigorous intensity NMES prescription which can improve aerobic exercise capacity and dissipate fatigue may be required to see sufficient improvements in HR-QoL subscales such as function QoL.
Specific HR-QoL outcomes were reported in studies for faecal incontinence in low rectal cancer [23] and dysphagia in nasopharyngeal carcinoma patients [24] , highlighting the diverse nature of HR-QoL assessment in cancer survivors. In breast cancer patients with lymphedema, Belmonte et al. [21] reported improvements in HR-QoL following NMES which met the minimal clinically important change score as reported by Eton et al. [37] , a finding not replicated in the control group receiving manual drainage. Whilst the magnitude of change was larger in the NMES group, statistical power was noted as a limitation limiting conclusions that can be drawn.
Interestingly, muscle strength was not a commonly reported outcome, and overall, meta-analysis of pooled effect from two RCTs did not demonstrate effectiveness of NMES over standard care in this outcome. However, two factors must be considered. First, Maddocks et al. [25] reported similar improvements in lower limb muscle strength (+ 22%) to those reported in a healthy elderly population (+ 15%) after 8 weeks of HF-NMES [13] . A small sample size conferring a lack of statistical power may have contributed to this finding. Secondly, poor adherence to unsupervised home-based interventions may lead to an inadequate exercise dosage for a training effect. Exercise intensity, mostly reported as visible muscle contractions or maximum tolerable intensities, may also be a contributing factor. Strength improvements from NMES are linearly related to NMES training intensity and therapeutic exercise intensities of 15-25% of maximal voluntary contraction (MVC) have been noted [38] . No studies included in this review reported training intensity as a percentage of MVC. In addition, a habituation period of 1-2 may be required to achieve these strengthening thresholds and to identify non-responders [19] . Indeed, 10% of patient groups and elderly cohorts do not tolerate NMES [19, 39] and an extended intervention period may be required to realise the true magnitude of adaptation to NMES stimulus in the elderly [40] . Therefore, habituation to NMES should be considered in future studies. This will allow practitioners to identify non-responders, and for them, consider alternative therapeutic strategies.
The optimal parameters for the safe use of NMES across all cancer populations cannot be determined from the studies included in this review. Only three studies [22, 25, 26] explicitly reported no adverse events and these were all related to individuals with lung cancer (NSCLC and metastatic lung cancer). NMES in the main appeared to be well tolerated with only one study reporting minor adverse events [21] . Skin irritations are not uncommon in NMES application [41] ; however, it is interesting to note the population (post breast cancer lymphedema patients) and the treatment parameters employed in this case (carrier frequency − 0.31-6.16 Hz, modulation between 400 and 1200 Hz, low offset voltage between + 12 and − 12 V). The author did report that after stimulation intensity was reduced, skin irritations did not reoccur. The high intensity in this study was likely required due to the higher levels of fluid present within the tissue.
Prescription [42] , this remains a common find in NMES research [43] . The diverse cancer populations in the included studies is acknowledged and may in part contribute to this finding with respect to the site of application, and variables such as frequency and intensity, and electrode size and placement. NMES was predominantly prescribed in those unable to partake in voluntary exercise due to their underlying disease or who were determined to be at risk of harm [22] and to combat secondary complications of cancer treatment relating to muscle weakness with seven studies involving participants who were post treatment. Studies included in this review where indices of physical function were the primary outcomes [22, 25, 26, 29] adopted a homogenous prescription approach (3-5×/week, 50-63.3 Hz, 300-400 μs). Although this prescription has been successful and safe in other patient groups (i.e. COPD, CHF), including those with implantable cardioverter defibrillators (when delivered to lower limbs) [44, 45] , such a general approach in cancer survivors may mask NMES's potential, given that cancer survivors can experience day to day variability in their readiness to train. The prescription of voluntary exercise in cancer survivorship is mostly individualised and adapted to optimise the therapeutic effect and minimise injury [46] . However, whilst voluntary exercise prescription adheres to the principles of training, NMES prescription in cancer survivors currently does not.
Specificity, the prescription of exercise designed to improve the primary outcome of interest, is another recognised principle of exercise training in cancer survivorship [46] that warrants further consideration in NMES prescription to improve physical function. Three of the included studies which considered the effects of NMES on submaximal exercise capacity employed high frequency protocols (50-63.3 Hz), and demonstrated negative results. The application of high frequency NMES favours adaptations in muscle strength [12] . Current exercise oncology guidelines recommend the inclusion of aerobic exercise [6] and where the outcomes of interest include both strength and exercise capacity, employing both low and high frequency NMES modalities may be more efficacious in future studies with acknowledgement that adaptations to low and high frequency NMES are uniquely different [47] .
In this review, NMES sessions were mostly delivered in the hospital or rehabilitation and outpatient clinics with only three being home-based interventions. Supervised sessions allow for regular oversight and are pragmatic as dose and compliance can be easily monitored. However, patient preferences may lean towards home-based interventions [9] . Self-report diaries are commonly used to monitor adherence to unsupervised home-based interventions; however, over-reporting is common [48] . Therefore, it is possible that home-based NMES may suffer from these same limitations, potentially masking benefits to primary outcomes. Future studies should consider cancer type and use adequate methods to monitor adherence for home-based interventions such as regular home visits or technologies such as app-based systems which can be used to monitor adherence, collect data, and provide remote support [49] .
Conclusion
The use of NMES in cancer rehabilitation is an emerging field. The current literature is limited by studies of poor quality and a lack of adequately powered RCTs. Existing studies suggest that NMES is safe and may be more effective than usual care for improving HR-QoL. However, its effects on objective measures of strength, body composition, and functional measures are less clear. A periodised approach including greater progression and defined prescriptive guidelines to maximise adherence to NMES prescription in the future may help improve its efficacy. High quality RCTs in cancer survivorship to definitively evaluate the effectiveness of NMES are required where the parameters chosen and progression patterns are tailored to the individual and outcomes of interest. 
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